INSPRA (eplerenone) Product Monograph. Page 2 of Table of This leaflet is a summary and will not tell you everything about INSPRA. X. Package leaflet: Information for the patient. Eplerenone 25 mg film-coated tablets. Eplerenone 50 mg film-coated tablets. Eplerenone. Read all of this leaflet . Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Inspra (eplerenone).

Author: Kazisho Akill
Country: Ghana
Language: English (Spanish)
Genre: Environment
Published (Last): 10 January 2017
Pages: 333
PDF File Size: 2.9 Mb
ePub File Size: 10.28 Mb
ISBN: 669-6-55353-407-3
Downloads: 28726
Price: Free* [*Free Regsitration Required]
Uploader: Tukasa

Because we aimed to investigate the effects of the packaage in real-world settings and because the dosage of all of the antihypertensive drugs including eplerenone could have been modified, the results do not necessarily reflect the effects eplerenonee eplerenone treatment alone. Eplerenone has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion.

Testicular weight and histology were not affected by Eplerenone in any test animal species at any dosage.

Eplerenone package insert pdf file

These considerations may guide selection of therapy. In addition, combination therapy consisting of drugs with different mechanisms of action has been recommended to further lower BP without causing adverse drug reactions ADRs [ 2 ].

The exclusion criteria included the following: Introduction Hypertension is a major public health issue in many countries. Therefore, we concluded that it is not necessary to call for special attention or implement new measures to ensure safety for concomitant use of eplerenone and other antihypertensive drugs. With respect to hyperkalemia, the current PMS confirmed that it is important to adhere to the contraindications stated on the package insert.

GPSP is the authorized standard for PMS studies of approved drugs in clinical practice, and no formal ethics committee approval or informed consent was necessary ellerenone conduct surveillance under this ordinance.


The BP changes from baseline were larger in the groups with higher baseline BP, and there was little change in the group with the lowest BP level at baseline.

Because recent studies have revealed that aldosterone can contribute to organ damage e. For example, potassium concentration data were unavailable unknown in subjects, which comprised Inaert rates increased with increasing duration of therapy. It is the active metabolite of the drug prednisone and is used especially in patients with liver failure, as these individuals are unable to metabolize prednisone into active prednisolone.

Subscribe to receive email notifications whenever new articles are published. For examination of changes in blood pressure, patients were excluded if eplerenone was contraindicated or used off-label. Medically reviewed on Oct 1, An extensive list of all adverse drug events that occurred in patients receiving eplerenone can be found in the package insert.

eplerenone Entire Monograph – Epocrates Online

Available for Android and iOS devices. Drugs packsge have produced thyroid tumors by this rodent-specific mechanism have not shown a similar effect in humans. Retention epleenone serum potassium is known to occur more frequently in patients with renal impairment. In a study in patients with low renin hypertension, blood pressure reductions in Blacks were smaller than those in whites during the initial titration period with Eplerenone. Highlights of prescribing information these highlights do not include all the information needed to use epogensafely and effectively.

The drug is indicated to improve the survival epkerenone stable patients with leftventricular systolic dysfunction ejection fraction eplerenone, a selective aldosteronereceptor antagonist, clinical therapeutics on deepdyve, inset largest online rental service for scholarly research with thousands of academic publications available at your fingertips.

However, recent studies have demonstrated that MRs are expressed in various organs including vascular endothelial and smooth muscle cells found in all cardiovascular tissues [ 10 — 14 ]. There were no exclusion criteria for patient registration. For inadequate blood pressure response, dosing may be increased to a maximum of 25 pavkage twice daily.


There are no adequate and well-controlled studies in pregnant women. Heart Failure amlodipinelisinoprilfurosemidecarvedilolmetoprololdiltiazemLasixspironolactonewarfarindigoxinhydralazineMore Concomitant renal impairment was observed in Mean peak plasma concentrations of Eplerenone are reached approximately 1.

Minimize eplerenpne risk of hyperkalemia with proper patient selection and monitoring [See Contraindications 4Adverse Reactions 6. Although precise definitions of severity were not provided, the physicians in charge were asked to judge the severity in a comprehensive manner, considering the disease duration, complications, concomitant medications, and other relevant factors.

The concentration of Eplerenone in human breast milk after oral administration is unknown. Aldosterone binds to mineralocorticoid receptors in both epithelial e.

eplerenone (INSPRA)

Among the 3, patients included in the safety analysis, Highlights of prescribing information these highlights do not include all the information needed to use injectafer safely and effectively. Lnsert clearance decreases at higher doses due to saturable hepatic metabolism. This is an open access article distributed under the Creative Commons Attribution Licensewhich permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A total of patients were treated for over 6 months and patients were treated for over 1 year. At the time eplerenone treatment was initiated, Eplerenone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Among these patients, Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular CV events, primarily strokes and MI.